Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Nuvectis Pharma, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 11 | 12 | +1 |
| Shares | 643.0K | 1.42M | +774.3K (+120.4%) |
| Value | $7.20M | $10.0M | +$2.85M (+39.6%) |
New holders (2)
Institutions that held Nuvectis Pharma, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 632,979 | $4.49M | 9.72% |
| Royal Bank of Canada | 76 | $1.00K | 0.00% |
Sold out (1)
Institutions that held Nuvectis Pharma, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Citadel Advisors LLC | 35,069 | $393.0K |